Main report

Genetics in Medicine

Volumn 8, Issue 5 SUPPL. 1, 2006, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACIDURIA; ADRENAL HYPERPLASIA; ALGORITHM; AMINOACIDURIA; BIOTINIDASE DEFICIENCY; CONSUMER; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; ECONOMIC EVALUATION; EDUCATION PROGRAM; EVIDENCE BASED MEDICINE; FATTY ACID OMEGA OXIDATION; GALACTOSEMIA; GENETIC SCREENING; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEARING LOSS; HEMOGLOBINOPATHY; HETEROZYGOTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL CARE; HUMAN; HYPOTHYROIDISM; INTERNET; LABORATORY DIAGNOSIS; LAW; MEDICAL DECISION MAKING; MEDICAL DOCUMENTATION; MEDICAL ETHICS; MEDICAL PROFESSION; MEDICAL SPECIALIST; MEDLINE; METABOLIC DISORDER; NEWBORN SCREENING; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PUBLIC HEALTH; REVIEW; SCORING SYSTEM; SCREENING TEST; STANDARDIZATION; TANDEM MASS SPECTROMETRY;

EID: 33748179301     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gim.0000223467.60151.02     Document Type: Review

References (53)

1. National Research Council, Committee for the Study of Inborn Errors of Metabolism; Genetic screening: programs, principles, and research. Washington, DC: National Academy of Sciences, 1975.
2. U.S. Congress, Office of Technology Assessment, Healthy Children: Investing in the Future, Appendix 1: Data and Methods Used in OTA'S Cost-Effectiveness Analysis of Strategies for Newborn Screening, 1988. Available at: http://www.wws.princeton.edu/cgi-bin/byteserv.prl/ota/disk2/1988/8819/ 881919.PDF Accessed April 7, 2006.
3. McCabe ERB. Principle of newborn screening for metabolic disease. Perinatol Neonatol 1982;6:63-73.
4. Therrell BL, Panny SR, Davidson A, Eckman J, et al. U.S. newborn screening system guidelines: statement of the Council of Regional Networks for Genetic Services (CORN). Screening 1992;1:135-147.
5. Therrell BL, Berenbaum SA, Manter-Kapanke V, Simmank J, Korman et al. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics 1998;101:583-590.
6. Pass KA, Lane PA, Fernhoff PM, Hinton CF, et al. US newborn screening guidelines II: follow-up of children, diagnosis, management, and evaluation. Statement of the Council of Regional Networks for Genetic Services (CORN). J Pediatr 2000;137:S1-S46.
7. Dhondt JL, Farriaux JP, Sailly JC, Lebrun T. Economic evaluation of cost-benefit ratio of neonatal screening procedure for phenylketonuria and hypothyroidism. J Inher Metab Dis 1991;14:633-639.
8. Tsevat J, Wong JB, Pauker SG, Steinberg MH. Neonatal screening for sickle cell disease: a cost-effectiveness analysis. J Pediatr 1991;118:546-554.
9. Wright L, Brown A, Davidson-Mundt A. Newborn screening: the miracle and the challenge. J Pediatr Nursing 1992;7:26-42.
10. Pollitt RJ, Green A, McCabe CJ, Booth A, et al. Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Health Technol Assess 1997;1:1-202. Review.
11. Guthrie R. Screening for "inborn errors of metabolism" in the newborn infant - A Multiple test program. Birth Defects 1968;4:92-98.
12. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963;32:338-343.
13. Academy of Pediatrics. Serving the family from birth to the medical home: A report from the Newborn Screening Task Force convened in Washington DC, May 10-11, 1999. Pediatrics 2000;106:383-427.
14. Wilson JM, Jungner YG. Principles and practice of screening for disease. Geneva: World Health Organization, 1968.
15. Levy HL. Newborn screening by tandem mass spectrometry: a new era. Clin Chem 1998;44:2401-2402.
16. Bailey DB. Newborn screening for fragile X syndrome. Ment Retard Dev Disabil Res Rev 2004;10:3-10.
17. Weatherall DJ, Clegg JB. The thallasemia syndromes 4th ed. Oxford: Blackwell Science; 2000.
18. Chace DH, Kalas TA, Naylor EW. Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin Chem 2003;49:1797-1817.
19. Meredith-Malloy N. Newborn Screening Quality Assurance Program: 2002 Tandem Mass Spectrometry Annual Summary Report. Atlanta: Centers for Disease Control and Prevention. 2003.
20. Rinaldo P, Tortorelli S, Matern M. Recent developments and new applications of tandem mass spectrometry in newborn screening. Curr Opini Pediatr 2004;16:427-433.
21. Marsden D, Larson CA. Emerging role for tandem mass spectrometry in detecting congenital adrenal hyperplasia. Clin Chem 2004;50:467-468.
22. Willi SM, Moshang T. Diagnostic dilemmas. Results of screening tests for congenital hypothyroidism. Pediatr Clini North Am 1991;38:555-566.
23. Lacey JM, Minutti CZ, Magera MJ, Tauscher AL, et al. Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry. Clin Chem 2004;50:621-625.
24. Ranieri E, Lewis B, Morris CP, et al. Neonatal screening using combined biochemical and DNA-based techniques. In: Dodge JA, Brock DJH, Widdicomb JH, editors. Cystic Fibrosis: Current Topics. Chichester, UK: John Wiley & Sons, 1996:181-206.
25. Blau N, Thony B, Cotton RGH, Hyland K. Disorders of tetrahydrobiopterin and related biogenic aminesIn: Scriver CR etal, editors. The Metabolic and Molecular Bases of Inherited Disease, 8 ed. New York: McGraw-Hill, 2001:1725-1776.
26. Report of a WHO Scientific Group. Screening for inborn errors of metabolism. World Health Organization Tech Report Series No. 401, 1968.
27. Holtzman A, Watson MS. Task Force on Genetic Testing: Promoting Safe and Effective Genetic Testing in the United States. Baltimore: Johns Hopkins Press, 1997.
28. Howse J, Katz M. The importance of newborn screening. Pediatrics 2000;106:595.-
29. Frankenburg WK. Selection of diseases and tests in pediatric screening. Pediatrics 1974;54:612-616.
30. Therrell BL. U.S. newborn screening policy dilemmas for the twenty-first century. Molec Genet Metab 2001;74:64-74.
31. American Academy of Pediatrics. Medical Home Initiatives for Children with Special Needs Project Advisory Committee. The medical home. Pediatrics 2002;110:184-186.
32. American Academy of Pediatrics Steering Committee on Quality Improvement and Management. Classifying recommendations for clinical practice guidelines. Pediatrics 2004;114:874-877.
33. Genetic Evaluation of Hearing Loss Expert Panel. Genetics evaluation guidelines for the etiologic diagnosis of congenital hearing loss. Genet Med 2002;4:162-171.
34. Young SS, Kharrazi M, Pearl M, Cunningham G. Cystic fibrosis screening in newborns: results from existing programs. Curr Opin in Pulm Med 2001;7:427-433.
35. Merelle ME, Nagelkerke AF, Lees CM, Dezateux C. Newborn screening for cystic fibrosis. Cochrane Database Syst Rev 2001;3:CD001402. Review.
36. Council of Regional Networks for Genetic Services (CORN), Sickle Cell, Thalassemia and Other Hemoglobin Variants Subcommittee. Guidelines for the follow-up hemoglobinopathy carriers detected by newborn screening, 1995.
37. Refsum H, Fredriksen A, Meyer K, Ueland PM, Kase BF. Birth prevalence of homocystinuria. J Pediatr 2004;144:830-832.
38. American Academy of Pediatrics Subcommittee on Management. Clinical Practice Guidelines 2004. Management of hyperbilirubinemia in the newborn infant 35 or more weeks gestation. Pediatrics 2004;114:297-316.
39. Eaton RB, Comeau AM, Zytkovicz TH, Larson C. Newborn screening: new developments in a proven field. Clin Lab Sci 2002;15:239-44.
40. Larson CA. Congenital Hypothyroidism. In: Pediatric Endocrinology: A Practical Clinical Guide. Radovick S, MacGillivray MH, eds., Totowa, NJ, Humana Press, 2003:275-290.
41. Panepinto JA, Magid D, Rewers MJ, Lane PA. Universal versus targeted screening of infants for sickle cell disease: a cost-effectiveness analysis. J Pediatr 2000;136:201-208.
42. Insinga RP, Laessig RH, Hoffman GL. Newborn screening with tandem mass spectrometry: examining its cost-effectiveness in the Wisconsin Newborn Screening Panel. J Pediatr 2002;141:524-531.
43. Keren R, Helfand M, Homer C, McPhillips H, Lieu TA. Projected cost-effectiveness of statewide universal newborn hearing screening. Pediatrics 2002;110:855-864.
44. Schoen EJ, Baker JC, Colby CJ, To TT. Cost-benefit analysis of universal tandem mass spectrometry for newborn screening. Pediatrics 2002;110:781-786.
45. Venditti LN, Venditti CP, Berry GT, Kaplan PB, et al. Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis. Pediatrics 2003;112:1005-1015.
46. Pandor A, Eastham J, Beverley C, Chilcott J, Paisley S. Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review. Health Technol Assess 2004;8:1-121.
47. PriceWaterhouseCoopers. Newborn screening programs: an overview of cost and financing, (January 2001) Available at: http://www.marchofdimes.com/files/ Final_PWC_NBS_Report2.pdf. Accessed May 18, 2006.
48. Washington State Department of Health. Least burden and cost benefit analysis of newborn screening for metabolic disorders, (2003) Available at: http://apps.leg-.wa.gov/WAC/default.aspx?cite=246-650. Accessed May 18, 2006.
49. Angus DC, Barnato AE, Linde-Zwirble WT, Weissfeld LA, et al. Robert Wood Johnson Foundation ICU End-of- Life Peer Group. Use of intensive care at the end of life in the United States: an epidemiologic study. Crit Care Med 2004;32:638-643.
50. Economic costs associated with mental retardation, cerebral palsy, hearing loss, and vision impairment, United States, 2003. Morb Mortal Wkly Rep 2004;53 (3):57-59.
51. Carroll AE, Downs SM. A comprehensive cost-utility analysis of newborn screening. Pediatrics 2006;117:287-295.
52. Keren R, Helfand M, Homer C, McPhillips H, Lieu TA. Projected cost-effectiveness of statewide universal newborn hearing screening. Pediatrics 2002;110:855-864.
53. Fearing MK, Levy H. Expanded newborn screening using tandem mass spectrometry. Adv Pedatr 2003;50:81-111.